localnews.ie

Merck Sharp & Dohme granted Supreme Court appeal in Clonmel Healthcare patent case

By Fionn Kelly

Historic decision · Decision date:

The Supreme Court will decide how to apply EU rules on supplementary protection certificates, after a High Court ruling that revoked a certificate for a combined cholesterol drug.

The Supreme Court has granted Merck Sharp & Dohme Corp leave to appeal against a Court of Appeal decision in its patent dispute with Clonmel Healthcare Limited, in a determination dated 4 August 2021. The Court found that the case raises matters of general public importance about how Article 3 of the EU Supplementary Protection Certificate Regulation should be interpreted and applied.

The certificate at the centre of the case, No. 2005/001, was granted in 2005 for Inegy, a cholesterol-reducing product combining two active ingredients, ezetimibe and simvastatin. Merck holds the patent that covers ezetimibe, which was granted by the European Patent Office on 19 May 1999. The company had already obtained an earlier certificate in 2003 for ezetimibe alone, sold as Ezetrol.

Merck sued Clonmel Healthcare for alleged infringement of its rights under the 2005 certificate. Clonmel counterclaimed that the certificate was invalid. The High Court (Justice McDonald) agreed on 11 February 2020. He declared the certificate invalid under Article 3(a) and (c) of the Regulation and ordered it revoked.

The Court of Appeal dismissed Merck's appeal. It held that, under Article 3(a), the product must fall under the invention covered by the patent. Ezetimibe did, but simvastatin was already a known ingredient covered by a different patent. Under Article 3(c), it held that the protected product was ezetimibe alone, which already had an earlier certificate.

Merck argues that the Court of Appeal used the wrong test, which it says would require a burdensome assessment of inventiveness supported by expert evidence. It says the correct test matters because the Irish courts and the Intellectual Property Office apply it to certificate applications and challenges. It says its group holds 24 other certificates and that hundreds are in force in Ireland.

Clonmel opposed the application. It argued that rulings of the Court of Justice of the European Union already give national courts enough guidance. It added that the certificate in this case has expired. A third ground, under Article 3(d), is not part of the application for leave. The Supreme Court noted the importance of the pharmaceutical industry in Ireland. It said the issues may have implications for other certificates and that it would be in the public interest to give further clarity. The issues may be refined at case management. The panel was Justice MacMenamin, Justice Charleton and Justice Woulfe.

Sources

Source: Courts Service of Ireland. Read the linked determination for the court’s exact decision.

Request a correction or removal